TY - JOUR AU - 최한곤 DA - 2018/01 PY - 2018 UR - https://www.sciencedirect.com/science/article/pii/S0927776517308573 UR - https://repository.hanyang.ac.kr/handle/20.500.11754/80904 AB - The aim of this research was to compare three strategies for enhancing the solubility of poorly water-soluble revaprazan hydrochloride: solid dispersion, solid SNEDDS and inclusion compound. The influence of polymers, surfactants and oils on the drug solubility was assessed, and via the chosen carriers, the three types of formulations were prepared utilising spray drying technique. Their physicochemical properties, solubility, dissolution and pharmacokinetics in rats were performed compared with revaprazan powder. Among the liquid SNEDDS formulations assessed, the compositions of revaprazan, peceol, Tweed 80 and Labrasol (10:15:55:30, weight ratio) provided the smallest emulsion size. Moreover, this liquid SNEDDS and dextran were suspended/dissolved in distilled water, and spray-dried, producing an optimal revaprazan-loaded solid SNEDDS. The appropriate solid dispersion and inclusion compound were composed of revaprazan, hydroxypropylmethylcellulose and cremophor A25 (5:1.4:5.6) and drug and hydroxyl-beta-cyclodextrin (2.5:8.77), respectively. The crystalline drug was converted to an amorphous state in all formulations. In the solid dispersion, the drug was attached to the hydrophilic carrier. The solid SNEDDS and inclusion compound contained aggregate microspheres and separate microspheres, respectively. All formulations significantly increased the drug solubility, dissolution, plasma concentration and AUC compared with revaprazan powder. These properties were ranked in the order solid dispersion >= solid SNEDDS > inclusion compound. Particularly, the solid dispersion improved about 9500 fold drug solubility and 10-fold oral bioavailability. Thus, the improved properties were considerably dependent upon these techniques, although all of the techniques employed similar mechanisms. Among the strategies checked, the solid dispersion system would be recommended as an oral revaprazan-loaded pharmaceutical product. (C) 2017 Elsevier B.V. All rights reserved. PB - ELSEVIER SCIENCE BV KW - Revaprazan hydrochloride KW - Solid dispersion KW - Solid SNEDDS KW - inclusion compound KW - Solubility KW - Crystallinity KW - Bioavailability TI - Comparison of a revaprazan-loaded solid dispersion, solid SNEDDS and inclusion compound: Physicochemical characterisation and pharmacokinetics VL - 162 DO - 10.1016/j.colsurfb.2017.12.017 T2 - COLLOIDS AND SURFACES B-BIOINTERFACES ER -